Amy Hagstrom Miller on Today’s FDA Mifepristone Announcement

Today’s FDA announcement of a label change to Mifepristone is a significant advancement for women in the United States.  All of us at Whole Woman’s Health are thrilled that the updated FDA labeling reflects evidence based care that is best for women. People who visit our clinics deserve options for abortion care without worrying about medically unnecessary obstacles and this change allows for more women to get the care they deserve.
We are particularly encouraged that this updated labeling could expand the availability of abortion in Texas, where  anti-choice politicians continue to interfere in women’s personal health decisions, enacting laws such as HB2 that deny women the ability to make their own decisions about whether and when to become a parent.
Prior to HB2, 40 to 50% of our patients at Whole Woman’s Health chose medication abortion. Since HB2 went into effect, that figure has decreased dramatically. For the past two years only…

View original post 151 more words

Advertisements